TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02822209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-C30
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire - patient
Description: The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction questionnaire - patient
Description: The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire - general practitioner or home nurse
Description: The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction questionnaire - general practitioner or home nurse
Description: The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-LC13
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-LC13
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
Study: NCT02394964

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
Study: NCT01172639

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: Sulfasalazine tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide
Description: Leflunomide tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone tablet
Study: NCT05469113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study: NCT05767814

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.

Intervention type: OTHER
Intervention: Phenotyping of synovial immune and stromal cells
Description: Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
Study: NCT02798913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short DAPT
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long DAPT
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
Study: NCT04011397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
Study: NCT02764177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: The protein drink was administered during this trial

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: The carbohydrate drink was administered in this trial
Study: NCT03487263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: chimeric monoclonal antibody against human IC14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: chimeric monoclonal antibody against human IC14
Study: NCT02866071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: 50mg IN Ketamine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Comparator
Description: 50mg IN Placebo
Study: NCT04651556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate & bupivacaine
Description: intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol & ketorolac
Description: parenteral analgesics
Study: NCT01624597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-vehicle video feedback
Description: An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent communication
Description: Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent communication
Description: Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
Study: NCT02204319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold laser
Description: Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
Study: NCT00383747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: 14mg transdermal nicotine application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 14mg transdermal nicotine application
Study: NCT03432650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + dexamethasone
Description: Anesthetic that will help treat pain and sensation after hip arthroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will help guide the anesthesiologist in performing the nerve block
Study: NCT04636957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution
Description: 0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3% solution
Description: 0.4mL/vial, each vial contains 1.2mg ciprofloxacin
Study: NCT00711997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTA-H19
Description: Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
Study: NCT02672397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional Epidural Education
Description: All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional Epidural Education
Description: All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
Study: NCT02314585

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
Study: NCT04970381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
Study: NCT03686618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion
Study: NCT04531813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425)
Description: Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
Study: NCT03864666

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100 mg
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR 200 mg
Description: Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR 200 mg
Description: Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
Study: NCT03383692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
Study: NCT05865847

Intervention type: OTHER
Intervention: Not applicable, this is an observational study
Description: Not applicable, this is an observational study
Study: NCT04068740

Intervention type: PROCEDURE
Intervention: Surgical treatment of valvular heart disease
Description: Valve replacement or repair

Intervention type: PROCEDURE
Intervention: Surgical treatment of valvular heart disease
Description: Valve replacement or repair

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual treatment
Description: Virtual valve replacement or repair surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual treatment
Description: Virtual valve replacement or repair surgery
Study: NCT01653327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
Study: NCT04531813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control-Sodium lauryl sulfate (SLS)
Description: Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: A blank patch was applied to the Negative Control test site.
Study: NCT01430078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet
Study: NCT01653327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01430078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: solution via oral capsule
Study: NCT04061733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel injection
Description: Hydrogel injection
Study: NCT02073656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT02073656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02431806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Description: Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Description: Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
Study: NCT03538067

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
Study: NCT01948583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
Study: NCT02668159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish peptide supplement
Description: 6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish peptide + Vitamin D3 supplements
Description: 6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 tablets of placebos administered prior to one the OGTT
Study: NCT01666210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-DP (Dexamethasone punctum plug)
Description: Sustained and tapered release of dexamethasone from hydrogel punctum plug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Punctum Plug
Description: Hydrogel punctum plug without dexamethasone
Study: NCT01840800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03000530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo